A Phase 2 interventional study of URC102 0.25mg and URC102 0.5mg in Gout and Hyperuricemia, sponsored by JW Pharmaceutical. Completed at 1 site in Korea, Republic of. Open to male participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-03-08.
Sponsored by JW Pharmaceutical · Phase 2, Interventional, and Treatment
The purpose of this study is to assess safety, PK/PD and Urate Lowering Effect of URC102 in gout patients with hyperuricemia
232 studies on the registry are indexed under Gout; 45 are open to participants now.
This study's enrollment of 64 is below the median of 121 across 202 interventional studies indexed under Gout.
Browse Gout studies →JW Pharmaceutical is the lead sponsor of 75 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Placebo x 2weeks
Drug: placebo
0.25mg URC102 x 2weeks
Drug: URC102 0.25mg
0.5mg URC102 x 2weeks
Drug: URC102 0.5mg
1.0mg URC102 x 2weeks
Drug: URC102 1.0mg
2.0mg URC102 x 2weeks
Drug: URC102 2.0mg
Trend of serum uric acid reduction and trend of serum uric acid levels
Frequency of patients with serum uric acid level reduced to \< 6.0 mg/dL and \< 5.0 mg/dL at each measurement
Time frame: weekly for 3weeks
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
JW Pharmaceutical